StreetInsider.com News Articles

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Wed, 14 Oct 2026 09:05:00 -0400

Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience

PRINCETON, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the publication of three-year real-world findings from an interim analysis of the XLH Disease Monitoring Program (DMP) in the Journal of Bone and Mineral Research. The analysis assessed serum phosphate levels and patient-reported pain, stiffness, and physical function at years 1 and 3 among adults with X-linked hypophosphatemia (XLH) treated with burosumab or

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Wed, 14 Oct 2026 09:05:00 -0400

Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Wed, 14 Oct 2026 09:05:00 -0400

Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience

Three-Year Real-World Study Compares Burosumab Treatment with Oral Phosphate and Active Vitamin D in Adults with XLH

Wed, 14 Oct 2026 09:05:00 -0400

Publication in the Journal of Bone and Mineral Research offers new insight into the long-term XLH treatment experience

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Mon, 12 Oct 2026 02:00:00 -0400

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1
Median time-to-next-treatment (TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1
Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)-- Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co.,

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Mon, 12 Oct 2026 02:00:00 -0400

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1
Median time-to-next-treatment (TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1
Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)-- Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co.,

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Mon, 12 Oct 2026 02:00:00 -0400

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1
Median time-to-next-treatment (TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1
Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)-- Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co.,

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

Mon, 12 Oct 2026 02:00:00 -0400

Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1
Median time-to-next-treatment (TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1
Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)-- Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co.,

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

GALASHIELS & MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America.

Under the

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

Under the

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

Under the

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

Under the

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

Under the

Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America

Tue, 29 Sep 2026 08:00:00 -0400

This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.
Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.
The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.

Under the

European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union